Message from the President:
Autumn is my favourite season. It is a time for harvesting the bounties of my gardens and benefiting from the hard work of my local farmers. It is a time to bask in all the colours, shapes and varieties of sunflowers growing in my yard. It is a time for routine with the end of lazy summer days and the start of school.
This September has brought multiple new layers and complexities with it. As we enter a second wave of the Coronavirus across most of the country, we will need to continue to think about how we keep ourselves, our families, and our patients safe. In a recent issue of JointHealth™ insight, a publication by Arthritis Consumers Experts, they provide practical advice on informed decision making during a pandemic. Not only is the information helpful for the arthritis patient community, but also for us, with helpful decision-making tools, activity risk level assessment and tips for reducing your exposure to the virus. Now, more than ever, we need to continue to work together to stay safe.
This newsletter contains glimpses of the many activities our board, our members and partner organizations are undertaking. Remember to stay connected with us through our website, Facebook, and Twitter accounts. If you have time and passion to spare, we would love to hear from you.
Stay safe, stay well, and stay kind.
email@example.comYou are receiving this AHPA newsbrief because you are on our AHPA membership list. If you would like to unsubscribe or update your subscription preferences please follow the links at the bottom of the newsletter.
2020 AHPA Clinical Innovation Award
CRA Telehealth Working Group
Sign up to receive updates and resources from the Canadian Rheumatology Association
2020 AHPA Pre-Course Notes: A six-month series: Canadian Spondylitis Association (CSA) - Graeme Reed (CSA president & patient volunteer
Our Online Presence
Recent Articles and Online Resources: AFF With Bisphosphonates Highest in Asians Study Confirms
In lieu of random eblasts, we will continue to distribute the Friday Newsflash when required. Information to be contained in these eblasts should be directed to firstname.lastname@example.org by Wednesdays at the latest. This is an effort to decrease the number of emails you receive and to better manage the efforts and time of our volunteers.
2020 AHPA Clinical Innovation Award
The AHPA Clinical Innovation Award was created to recognize AHPA members who have designed and implemented an innovative clinical project or related initiative that benefits the lives of Canadians living with arthritis. This award will showcase clinical initiatives, including those that assess, treat, educate or otherwise support people living with arthritis in new and innovative ways.
Click here to download the Application Form and Grading Rubric
We invite allied health professional AHPA members who have undertaken within the past 5 years a clinical project or related initiative with relevance to the field of rheumatology to submit an application. Projects should be beyond the concept or proposal stage and applicants are asked to provide early/initial or final results in the form of process and/or outcome measures/data to show the impact of their initiative on the target group. Clinicians can self-nominate or AHPA members and non-members can also nominate an AHPA member with that member’s permission. The award is intended for non-physician health professionals. This award is non-renewable and recipients may only receive the award once.
Nomination and application process
The applicant should submit the application form requests project summary information, including the project title, keywords, aim or purpose, target audience, an overview of initiative or project, and any evaluation results. The project summary should be single-spaced using 12 point font and 1-inch margins and be 250 words or less. You may use ONE diagram/flowchart/visual to support your application. The deadline for applications is midnight (EST) on Friday, December 4th, 2020. The submission may be sent by e-mail or regular post to:
Chair, AHPA Professional and Career Development Committee
c/o St George Physiotherapy Clinic
180 Bloor St West, Suite 1202
A decision will be announced by Thursday, December 24th, 2020 and the award will be presented at the AHPA AGM during the 2021 CRA/AHPA meeting to be held virtually. The Clinical Innovation Award winner and the details of the innovation will be written up in the AHPA News Brief and on the AHPA web site. The successful candidate will also be required to present their clinical innovation at one of the AHPA-sponsored workshops at the Canadian Rheumatology Association Annual Scientific Meeting the following year. In order to assist in the dissemination of innovative ideas, all project titles, and applicant’s names and email addresses will also be listed on the AHPA web site.
Selection process and award
Applications meeting the basic criteria will be reviewed by a committee with the following representatives: an AHPA board member, an Arthritis Society staff member, a person living with arthritis and a rheumatologist. The top-rated application, based on clinical merit, creativity and potential significance to the field, will receive:
- $250 award in the form of a cheque
- Acknowledgement of your award and project at the 2021 CRA/AHPA Annual General Meeting.
CRA Telehealth Working Group
2020 AHPA Pre-Course Notes: A six-month series
Thank you to Kristin Dillon* and Karen Gordon* for sharing their notes from the 2020 AHPA Pre-Course
Canadian Spondylitis Association (CSA) Graeme Reed (CSA president & patient volunteer)
Spondyloarthritis survey results:
62% of those with chronic pain have mental health issues (vs 42% w/o chronic pain)
CSA: patient volunteers; social media, info sessions, blog posts; guidebooks; Peer to Peer, telephone and email support
CSA local support groups including Toronto, Hamilton. Durham, Mississauga, Ottawa
Remember to refer
We held a successful virtual Strategic Planning Meeting on September 12th. Thank you to our board members from coast to coast (Newfoundland, Nova Scotia, Ontario, Alberta, and British Colombia) for dedicating their time, and their Saturday, to this meeting. Your board is working hard to pivot our activities to virtual platforms to meet our three main strategic priorities of Knowledge Translation, Engagement and Sustainability. Stay tuned for further information and upcoming changes.
Our Pre-course planning committee continues to work towards transitioning to an online learning platform to provide you with the excellent speakers and content you have come to expect.
Our Online Presence
Recent Articles and Online Resources
AFF With Bisphosphonates Highest in Asians Study Confirms
Bisphosphonates are effective in reducing hip and osteoporotic fractures. However, concerns about atypical femur fractures have contributed to substantially decreased bisphosphonate use, and the incidence of hip fractures may be increasing. Important uncertainties remain regarding the association between atypical femur fractures and bisphosphonates and other risk factors.
We studied women 50 years of age or older who were receiving bisphosphonates and who were enrolled in the Kaiser Permanente Southern California health care system; women were followed from January 1, 2007, to November 30, 2017. The primary outcome was atypical femur fracture. Data on risk factors, including bisphosphonate use, were obtained from electronic health records. Fractures were radiographically adjudicated. Multivariable Cox models were used. The risk–benefit profile was modeled for 1 to 10 years of bisphosphonate use to compare associated atypical fractures with other fractures prevented.
Among 196,129 women, 277 atypical femur fractures occurred. After multivariable adjustment, the risk of atypical fracture increased with longer duration of bisphosphonate use: the hazard ratio as compared with less than 3 months increased from 8.86 (95% confidence interval [CI], 2.79 to 28.20) for 3 years to less than 5 years to 43.51 (95% CI, 13.70 to 138.15) for 8 years or more. Other risk factors included race (hazard ratio for Asians vs. Whites, 4.84; 95% CI, 3.57 to 6.56), height, weight, and glucocorticoid use. Bisphosphonate discontinuation was associated with a rapid decrease in the risk of atypical fracture. Decreases in the risk of osteoporotic and hip fractures during 1 to 10 years of bisphosphonate use far outweighed the increased risk of atypical fracture among Whites but less so among Asians. After 3 years, 149 hip fractures were prevented and 2 bisphosphonate-associated atypical fractures occurred in Whites, as compared with 91 and 8, respectively, in Asians.
The risk of atypical femur fracture increased with longer duration of bisphosphonate use and rapidly decreased after bisphosphonate discontinuation. Asians had a higher risk than Whites. The absolute risk of atypical femur fracture remained very low as compared with reductions in the risk of hip and other fractures with bisphosphonate treatment. (Funded by Kaiser Permanente and others.)
Next Newsbrief Deadline
The deadline for the September 2020 newsbrief will be October 18, 2020. Please send any contributions to Denise Jupp at email@example.com. We are particularly interested in notices of conferences or workshops, new resources for patients or health professionals and summaries of recent research/publications. We welcome contributions from members from all parts of the country.